ArticleJournal of molecular histology2025
Selenium nanoparticles mitigate chlorpyrifos-induced nephrotoxicity by modulating oxidative stress, inflammation, and the SIRT1/Nrf2/HO-1 signaling pathway.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- EGCG-mediated selenium nanoparticles protect against 5-fluorouracil-induced cardiotoxicity via Nrf2/Keap1 signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Selenium nanoparticle-enhanced resveratrol suppresses pulmonary inflammation and fibrogenesis in silicosis via redox-mediated inflammatory pathway modulation.Inflammopharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chlorpyrifos (CPF), a widely used pesticide, is associated with significant renal toxicity, raising concerns about its impact on kidney health. Selenium nanoparticles (Se NPs) have emerged as a potential therapeutic agent due to their beneficial properties. This study evaluated the effects of Se NPs against CPF-induced nephrotoxicity, focusing on oxidative stress, inflammation, and the SIRT1/Nrf2/HO-1 signaling pathway. Rats were administered CPF, with or without Se NPs, for 28 days. Renal function was assessed through biochemical markers, histopathological examination, and molecular analyses. CPF exposure significantly elevated serum creatinine, blood urea nitrogen, and Kim-1 levels, accompanied by histopathological damage in renal tissues. Se NPs treatment effectively restored renal function and attenuated structural abnormalities. CPF-induced oxidative stress was evident through increased lipid peroxidation and suppressed antioxidant enzymes and reduced glutathione (GSH), which were counteracted by Se NPs. Furthermore, CPF upregulated pro-inflammatory and apoptosis mediators (NF-κB, TNF-α, IL-6, iNOS, Bax, and caspase-3), while downregulating the anti-apoptotic Bcl-2. Se NPs mitigated these effects by suppressing inflammatory and apoptotic pathways, effects associated with decreased Keap1 and enhanced SIRT1, Nrf2, and HO-1. In conclusion, Se NPs confer protection against CPF-induced kidney injury by alleviating oxidative stress, inflammation, and apoptosis, and by modulating the SIRT1/Nrf2/HO-1 signaling. These findings underscore the potential of Se NPs as a therapeutic intervention for CPF-associated nephrotoxicity.
Indexed as
Identifiers
40742471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.